CL2020002574A1 - Análogos novedosos de glp-1 - Google Patents

Análogos novedosos de glp-1

Info

Publication number
CL2020002574A1
CL2020002574A1 CL2020002574A CL2020002574A CL2020002574A1 CL 2020002574 A1 CL2020002574 A1 CL 2020002574A1 CL 2020002574 A CL2020002574 A CL 2020002574A CL 2020002574 A CL2020002574 A CL 2020002574A CL 2020002574 A1 CL2020002574 A1 CL 2020002574A1
Authority
CL
Chile
Prior art keywords
analogs
glp
present disclosure
new
action
Prior art date
Application number
CL2020002574A
Other languages
English (en)
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao Burade
Pradeep Dinesh Shahi
Muthukumaran Natarajan
Ravishankara Madavati Nagaraja
Rishit Mansukhlal Zalawadia
Kunal Pandya
Brijeshkumar Patel
Dhiren Rameshchandra Joshi
Krunal Harishbhai Soni
Abhishek Tiwari
Vipulkumar Shankarbhai Patel
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of CL2020002574A1 publication Critical patent/CL2020002574A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

La presente revelación pertenece a los nuevos análogos del Glucagón como el Péptido-1 (GLP-1) (7-37) que tienen una secuencia de aminoácidos con Leu o Ile en el C-terminal. Los nuevos análogos son potentes agonistas del GLP-1 con un efecto adverso reducido y una mejor duración de la acción. La presente divulgación se refiere además a los derivados acilados de los nuevos análogos que han mejorado aún más la potencia y la duración de la acción y son adecuados para la administración oral. Los análogos de la presente divulgación pueden ser útiles en el tratamiento de la diabetes y la obesidad.
CL2020002574A 2018-04-05 2020-10-05 Análogos novedosos de glp-1 CL2020002574A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26

Publications (1)

Publication Number Publication Date
CL2020002574A1 true CL2020002574A1 (es) 2021-06-04

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002574A CL2020002574A1 (es) 2018-04-05 2020-10-05 Análogos novedosos de glp-1

Country Status (29)

Country Link
US (6) US11447535B2 (es)
EP (3) EP3774862B1 (es)
JP (2) JP7250814B2 (es)
KR (1) KR20200141469A (es)
CN (2) CN112236444A (es)
AU (2) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (2) DK4122954T3 (es)
EC (1) ECSP20070185A (es)
ES (1) ES2925678T3 (es)
FI (1) FI4122954T3 (es)
HR (1) HRP20221054T1 (es)
HU (1) HUE060135T2 (es)
IL (1) IL277483A (es)
JO (1) JOP20200251A1 (es)
LT (2) LT3774862T (es)
MX (1) MX2020010505A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (1) PL3774862T3 (es)
PT (1) PT3774862T (es)
RS (1) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (1) SI3774862T1 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774862B1 (en) * 2018-04-05 2022-06-08 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
IL301109A (en) * 2020-10-17 2023-05-01 Sun Pharmaceutical Ind Ltd Dual GLP-1/GIP agonists
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
EP4281464A1 (en) 2021-01-20 2023-11-29 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
CN117756914A (zh) * 2023-12-15 2024-03-26 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
TW200306202A (en) 2002-01-08 2003-11-16 Lilly Co Eli Extended glucagon-like peptide-1 analogs
AU2003272970B2 (en) 2002-10-11 2009-05-28 Sanwa Kagaku Kenkyusho Co. Ltd. GLP-1 derivatives and transmicosal absorption preparations thereof
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
RU2007134155A (ru) * 2005-03-18 2009-04-27 Ново Нордиск А/С (DK) Glp-1 соединения с увеличенным временем полужизни
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP2008539735A (ja) 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
CN101262874A (zh) 2005-09-08 2008-09-10 塔夫茨大学信托人 稳定化的glp-1类似物
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
WO2011073328A1 (en) 2009-12-16 2011-06-23 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
BR112012027545B1 (pt) 2010-04-27 2020-09-24 Betta Pharmaceuticals Co., Ltd. Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
ES2683372T3 (es) 2010-11-09 2018-09-26 Novo Nordisk A/S Derivados de GLP-1 acilados con un conector nuevo
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
EP2846824B1 (en) 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
US10000542B2 (en) 2012-05-08 2018-06-19 Novo Nordisk A/S Double-acylated GLP-1 derivatives
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
CN104870009B (zh) 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
BR112015030948A2 (pt) 2013-06-20 2017-09-19 Novo Nordisk As Derivados de glp-1 e usos dos mesmos
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
MX2015016875A (es) 2013-07-04 2016-04-07 Novo Nordisk As Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
KR102569036B1 (ko) * 2013-10-17 2023-08-23 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
JP2017502003A (ja) 2013-12-13 2017-01-19 メディミューン リミテッド プロテアーゼ耐性ペプチド
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017035432A1 (en) 2015-08-26 2017-03-02 Robert Doyle Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
AU2017277594A1 (en) 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
US10883132B2 (en) 2018-03-09 2021-01-05 Enzypep B.V. Chemo-enzymatic synthesis of Semaglutide, Liraglutide and GLP-1
EP3774862B1 (en) * 2018-04-05 2022-06-08 Sun Pharmaceutical Industries Limited Novel glp-1 analogues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
LT4122954T (lt) 2024-06-25
JP7250814B2 (ja) 2023-04-03
AU2019247936C1 (en) 2023-06-15
ES2925678T3 (es) 2022-10-19
RS63523B1 (sr) 2022-09-30
EP3774862A1 (en) 2021-02-17
ECSP20070185A (es) 2021-01-29
AU2023203430A1 (en) 2023-06-29
CA3095988A1 (en) 2019-10-10
DK4122954T3 (da) 2024-06-10
WO2019193576A1 (en) 2019-10-10
PT3774862T (pt) 2022-09-05
FI4122954T3 (fi) 2024-06-18
CO2020012425A2 (es) 2020-12-21
US20240199718A1 (en) 2024-06-20
EP4364751A3 (en) 2024-06-26
AU2019247936A1 (en) 2020-10-15
BR112020020419A2 (pt) 2021-01-19
PH12020551591A1 (en) 2021-08-16
SG11202009467YA (en) 2020-10-29
US11485766B2 (en) 2022-11-01
SI3774862T1 (sl) 2022-10-28
EP4122954B1 (en) 2024-04-03
LT3774862T (lt) 2022-09-12
DK3774862T3 (da) 2022-09-05
MX2020010505A (es) 2021-01-15
US20200362007A1 (en) 2020-11-19
JP2023078367A (ja) 2023-06-06
US20190309040A1 (en) 2019-10-10
JOP20200251A1 (ar) 2020-10-04
US20210206823A1 (en) 2021-07-08
EP4364751A2 (en) 2024-05-08
US11873328B2 (en) 2024-01-16
HRP20221054T1 (hr) 2022-11-11
PE20211417A1 (es) 2021-08-02
KR20200141469A (ko) 2020-12-18
US20220402991A1 (en) 2022-12-22
HUE060135T2 (hu) 2023-02-28
CN112236444A (zh) 2021-01-15
JP2021520346A (ja) 2021-08-19
US11866477B2 (en) 2024-01-09
CN117964735A (zh) 2024-05-03
AU2019247936B2 (en) 2023-03-02
ZA202306729B (en) 2024-03-27
PL3774862T3 (pl) 2022-10-03
EP3774862B1 (en) 2022-06-08
EP4122954A1 (en) 2023-01-25
US11242373B2 (en) 2022-02-08
US20220402992A1 (en) 2022-12-22
US11447535B2 (en) 2022-09-20
IL277483A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CL2020002574A1 (es) Análogos novedosos de glp-1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
CL2020002796A1 (es) Derivados de gip y usos de estos
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
PE20151770A1 (es) Compuesto peptidico
AR109274A2 (es) Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
AR099976A1 (es) Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4
PE20200606A1 (es) Composiciones solidas para administracion oral
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
GT201700224A (es) Proteína de unión a rgma y su uso
AR105284A1 (es) Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
PE20221518A1 (es) Analogos de incretina y sus usos
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada
EA202092017A1 (ru) Новые аналоги glp-1